Immediate antihypertensive treatment following an acute ischaemic stroke in patients with a history of hypertension may reduce their risk of recurrent stroke, a subgroup analysis of the CATIS* trial showed.
An observational study has found that high and increasing blood pressure (BP) from early adulthood into midlife seems to be associated with increased white matter hyperintensity volume (WMHV) and smaller brain volumes at 69 to 71 years of age.
New drug applications approved by US FDA as of 16 - 31 August 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Increasing body mass index (BMI), male sex, and certain comorbidities are factors associated with an elevated risk of opioid use in patients with migraine, according to results from the CaMEO* study presented at the recent American Headache Society conference (AHS 2019).
A history of migraine does not appear to affect the risk of cardiovascular disease (CVD) in postmenopausal women, a large observational study presented at the American Headache Society conference (AHS 2019) showed.
Seven healthcare organizations will collaborate with a pharmaceutical company on building an integrated care ecosystem among private healthcare professionals (HCPs) to manage noncommunicable diseases (NCDs).
Consuming polyphenol-rich pomegranate juice during pregnancy was associated with better microstructural development and functional connectivity in the brains of newborns with intrauterine growth restriction (IUGR), suggests preliminary evidence from a pilot randomized study.
Transcutaneous vagal nerve stimulation (tVNS) delivered through a device attached to the ear can help rebalance the autonomic nervous system of individuals aged ≥55 years, and thus promote healthy ageing, a new study suggests.
Atogepant, a novel oral calcitonin gene-related peptide (CGRP) receptor antagonist, has shown potential in prevention of migraine at a range of doses, according to a presentation at the recent American Headache Society conference (AHS 2019).
Low total cholesterol levels appear to carry increased major adverse cardiovascular events (MACE) hazard in older men without ischaemic heart disease (IHD) and not receiving statin therapy but not to those on statins, according to data from the CHAMP (Concord Health and Ageing in Men Project) cohort.